Raymond James & Associates Galmed Pharmaceuticals Ltd. Transaction History

Raymond James & Associates

  • $150 Billion
  • Q2 2024

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 08, 2023
SELL
$0.29 - $84.61 $5,191 - $1.51 Million
-17,900 Reduced 11.48%
138,040 $69,000
Q3 2022

Oct 25, 2022
SELL
$0.35 - $59.37 $525 - $89,055
-1,500 Reduced 0.95%
155,940 $49,000
Q2 2022

Aug 12, 2022
SELL
$0.44 - $1.77 $20,020 - $80,535
-45,500 Reduced 22.42%
157,440 $102,000
Q1 2022

May 11, 2022
SELL
$1.23 - $2.07 $738 - $1,242
-600 Reduced 0.29%
202,940 $323,000
Q4 2021

Feb 08, 2022
SELL
$1.75 - $3.03 $45,675 - $79,083
-26,100 Reduced 11.37%
203,540 $370,000
Q3 2021

Nov 02, 2021
BUY
$2.41 - $3.33 $52,477 - $72,510
21,775 Added 10.48%
229,640 $641,000
Q2 2021

Aug 11, 2021
BUY
$2.24 - $3.9 $131,922 - $229,686
58,894 Added 39.53%
207,865 $632,000
Q1 2021

May 14, 2021
BUY
$3.19 - $5.4 $27,453 - $46,472
8,606 Added 6.13%
148,971 $511,000
Q4 2020

Feb 12, 2021
SELL
$3.06 - $4.17 $269,904 - $367,810
-88,204 Reduced 38.59%
140,365 $437,000
Q3 2020

Nov 04, 2020
SELL
$3.46 - $5.69 $1.06 Million - $1.74 Million
-306,040 Reduced 57.25%
228,569 $807,000
Q2 2020

Jul 28, 2020
BUY
$3.22 - $6.08 $613,133 - $1.16 Million
190,414 Added 55.32%
534,609 $2.56 Million
Q1 2020

Apr 21, 2020
SELL
$3.3 - $6.84 $195,901 - $406,049
-59,364 Reduced 14.71%
344,195 $1.19 Million
Q4 2019

Feb 12, 2020
BUY
$3.61 - $6.75 $538,951 - $1.01 Million
149,294 Added 58.72%
403,559 $2.33 Million
Q3 2019

Nov 07, 2019
BUY
$4.62 - $7.11 $648,186 - $997,533
140,300 Added 123.11%
254,265 $1.22 Million
Q2 2019

Aug 06, 2019
BUY
$5.68 - $8.68 $151,883 - $232,103
26,740 Added 30.66%
113,965 $838,000
Q1 2019

May 06, 2019
BUY
$7.27 - $9.07 $7,444 - $9,287
1,024 Added 1.19%
87,225 $713,000
Q4 2018

Feb 11, 2019
BUY
$6.59 - $14.47 $90,704 - $199,165
13,764 Added 19.0%
86,201 $589,000
Q3 2018

Nov 14, 2018
BUY
$10.55 - $15.28 $764,210 - $1.11 Million
72,437 New
72,437 $984,000

About Galmed Pharmaceuticals Ltd.

GLMD Quotes by TradingView
  • Ticker GLMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,088,400
  • Market Cap $153M
  • Description
  • Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or t...
More about GLMD
Track This Portfolio

Track Raymond James & Associates Portfolio

Follow Raymond James & Associates and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email